Pipeline
At Almirall, we are committed to transforming the lives of patients through innovative research and development. Our pipeline represents a broad array of groundbreaking therapies, each designed to address some of the most pressing medical needs in dermatology.
Late stage pipeline
This dynamic pipeline showcases our dedication to advancing treatment options, leveraging cutting-edge science and technology to bring new solutions to the market. Here, you can explore our Late-stage pipeline, where we focus on delivering therapies that promise to make a meaningful impact on patient care.
14 results
Tirbanibulin
Actinic keratosisLife-cycle management
Registration
European Union
Tildrakizumab
Psoriatic arthritisLife-cycle management
Registration
European Union
Lebrikizumab
Paediatric atopic dermatitisLife-cycle management
Phase III
European Union
Lebrikizumab
Nummular eczemaLife-cycle management
Phase III
European Union
Anti-IL-1RAP mAb
Hidradenitis suppurativaNew Molecular Entity
Phase II
Worldwide
Anti-IL-1RAP mAb
Inflammatory skin diseaseNew Molecular Entity
Phase II
Worldwide
Anti-IL-21 mAb
Hidradenitis suppurativaNew Molecular Entity
Phase II
Worldwide
IL-2muFc
Inflammatory skin diseaseNew Molecular Entity
Phase II
Worldwide*
IL-2muFc
Atopic dermatitisNew Molecular Entity
Phase II
Worldwide**
IL-2muFc
Alopecia areataNew Molecular Entity
Phase II
Worldwide*
Readthrough inducer
Rare dermatology (RDEB/JEB)***New Molecular Entity
Phase I
Worldwide
Anti-IL-13/OX40L BsAb
Atopic dermatitisNew Molecular Entity
Phase I
Worldwide
SMOL oral
Th2-driven diseasesNew Molecular Entity
Discovery (advanced) / Preclinical
Worldwide
mRNA/LNP
Non-melanoma skin cancerNew Molecular Entity
Discovery (advanced) / Preclinical
Worldwide